Status:
COMPLETED
Convalescent Plasma Therapy in Patients With COVID-19
Lead Sponsor:
Biofarma
Collaborating Sponsors:
Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
Eijkman Institute for Molecular Biology
Conditions:
Convalescence
Corona Virus Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Scientists and medical workers all around the world were running out of time to manage COVID-19. Several studies have been done to understand the disease and ultimately to find possible treatment. Bas...
Detailed Description
The rational use of antibodies from the recovered patient's plasma as a natural neutralizing antibody to the cell-infected virus (plaques). Several expanded use of convalescent plasma therapy to sever...
Eligibility Criteria
Inclusion
- Confirmed COVID-19 case with RT-PCR
- Stage IIb of COVID-19 or higher
- Consent was given by the patient or legal guardian
Exclusion
- Pregnant
- History of anaphylactic reaction in previous blood product transfusion
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 22 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04407208
Start Date
May 1 2020
End Date
June 22 2020
Last Update
June 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gatot Soebroto central army presidential hospital
Jakarta Pusat, Indonesia, 10410